BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29777584)

  • 1. Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.
    Butcher NJ; Boot E; Lang AE; Andrade D; Vorstman J; McDonald-McGinn D; Bassett AS
    Am J Med Genet A; 2018 Oct; 176(10):2146-2159. PubMed ID: 29777584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Psychosis and movement disorders in an adolescent with 22q11.2 deletion syndrome].
    Zinkstok JR; Velders F; Rieken R; Houben M; Fiksinski A; van Amelsvoort TAMJ; Boot E
    Tijdschr Psychiatr; 2020; 62(3):229-233. PubMed ID: 32207133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
    Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
    Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myoclonic epilepsy, parkinsonism, schizophrenia and left-handedness as common neuropsychiatric features in 22q11.2 deletion syndrome.
    Fanella M; Frascarelli M; Lambiase C; Morano A; Unolt M; Liberati N; Fattouch J; Buzzanca A; Accinni T; Ceccanti M; Viganò A; Biondi M; Colonnese C; Giallonardo AT; Di Fabio F; Pizzuti A; Di Bonaventura C; Berardelli A
    J Med Genet; 2020 Mar; 57(3):151-159. PubMed ID: 31506323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dimensional structure of psychopathology in 22q11.2 Deletion Syndrome.
    Niarchou M; Moore TM; Tang SX; Calkins ME; McDonald-McGuinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
    J Psychiatr Res; 2017 Sep; 92():124-131. PubMed ID: 28433949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.
    Butcher NJ; Marras C; Pondal M; Rusjan P; Boot E; Christopher L; Repetto GM; Fritsch R; Chow EWC; Masellis M; Strafella AP; Lang AE; Bassett AS
    Brain; 2017 May; 140(5):1371-1383. PubMed ID: 28369257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study.
    Gothelf D; Schneider M; Green T; Debbané M; Frisch A; Glaser B; Zilkha H; Schaer M; Weizman A; Eliez S
    J Am Acad Child Adolesc Psychiatry; 2013 Nov; 52(11):1192-1203.e3. PubMed ID: 24157393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.
    Gothelf D; Law AJ; Frisch A; Chen J; Zarchi O; Michaelovsky E; Ren-Patterson R; Lipska BK; Carmel M; Kolachana B; Weizman A; Weinberger DR
    Biol Psychiatry; 2014 Mar; 75(5):406-13. PubMed ID: 23992923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the neuropsychiatric and neurocognitive phenotype in two microdeletion syndromes: velocardiofacial (22q11.2 deletion) and Williams (7q11.23 deletion) syndromes.
    Zarchi O; Diamond A; Weinberger R; Abbott D; Carmel M; Frisch A; Michaelovsky E; Gruber R; Green T; Weizman A; Gothelf D
    Eur Psychiatry; 2014 May; 29(4):203-10. PubMed ID: 24054518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.
    Van L; Boot E; Bassett AS
    Curr Opin Psychiatry; 2017 May; 30(3):191-196. PubMed ID: 28230630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catatonia in an adolescent with velo-cardio-facial syndrome.
    Faedda GL; Wachtel LE; Higgins AM; Shprintzen RJ
    Am J Med Genet A; 2015 Sep; 167A(9):2150-3. PubMed ID: 25832449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome.
    Monks S; Niarchou M; Davies AR; Walters JT; Williams N; Owen MJ; van den Bree MB; Murphy KC
    Schizophr Res; 2014 Mar; 153(1-3):231-6. PubMed ID: 24534796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep psychophysiological phenotyping of adolescents and adults with 22q11.2 deletion syndrome: a multilevel approach to defining core disease processes.
    Parker DA; Cubells JF; Imes SL; Ruban GA; Henshey BT; Massa NM; Walker EF; Duncan EJ; Ousley OY
    BMC Psychiatry; 2023 Jun; 23(1):425. PubMed ID: 37312091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome.
    Niarchou M; Calkins ME; Moore TM; Tang SX; McDonald-McGinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
    Schizophr Bull; 2018 Jun; 44(4):824-833. PubMed ID: 29040797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceived burden and neuropsychiatric morbidities in adults with 22q11.2 deletion syndrome.
    Karas DJ; Costain G; Chow EW; Bassett AS
    J Intellect Disabil Res; 2014 Feb; 58(2):198-210. PubMed ID: 23106770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental trajectories of brain structure in adolescents with 22q11.2 deletion syndrome: a longitudinal study.
    Gothelf D; Penniman L; Gu E; Eliez S; Reiss AL
    Schizophr Res; 2007 Nov; 96(1-3):72-81. PubMed ID: 17804201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
    Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
    Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Craniofacial dysmorphology in 22q11.2 deletion syndrome by 3D laser surface imaging and geometric morphometrics: illuminating the developmental relationship to risk for psychosis.
    Prasad S; Katina S; Hennessy RJ; Murphy KC; Bowman AW; Waddington JL
    Am J Med Genet A; 2015 Mar; 167A(3):529-36. PubMed ID: 25691406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study on immuno-psychiatry in the 22q11.2 deletion syndrome: A role for Th17 cells in psychosis?
    Vergaelen E; Schiweck C; Van Steeland K; Counotte J; Veling W; Swillen A; Drexhage H; Claes S
    Brain Behav Immun; 2018 May; 70():88-95. PubMed ID: 29567371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the potential association among sleep disturbances, cognitive impairments, and immune activation in 22q11.2 deletion syndrome.
    Yirmiya ET; Mekori-Domachevsky E; Weinberger R; Taler M; Carmel M; Gothelf D
    Am J Med Genet A; 2020 Mar; 182(3):461-468. PubMed ID: 31837200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.